Clinical trial / 2024
Continued treatment with tirzepatide maintained and further reduced weight, whereas switching to placebo led to substantial weight regain.
In this phase 3 trial, 783 adults completed a 36-week open-label tirzepatide lead-in period with diet and physical activity, achieving a mean weight reduction of 20.9%. At week 36, 670 participants were randomized to continue tirzepatide or switch to placebo for 52 weeks. Mean percent weight change from week 36 to 88 was -5.5% with tirzepatide compared to +14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001). Overall, 89.5% of tirzepatide participants maintained at least 80% of initial weight loss versus 16.6% on placebo. The most common adverse events were mostly mild to moderate gastrointestinal symptoms.
- Study type
- Phase 3, randomized withdrawal clinical trial
- Who was studied
- 670 adults with obesity or overweight and weight-related complications (excluding diabetes) who completed a 36-week lead-in period
- What was measured
- Mean percent change in weight from week 36 to week 88
THE PAPER
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA, SURMOUNT-4 Investigators. JAMA, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.